Progression‐free survival assessed per immune‐related or conventional response criteria, which is the better surrogate endpoint for overall survival in trials of immune‐checkpoint inhibitors in lung cancer: A systematic review and meta‐analysis
Abstract Progression‐free survival (PFS) has been used as a surrogate endpoint for overall survival (OS) in lung cancer trials. The pattern of response to immune‐checkpoint inhibitors (ICIs) differs from that to conventional chemotherapy, so immune‐related response evaluation criteria were proposed....
Enregistré dans:
| Auteurs principaux: | , , , |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
Wiley
2021
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/453ad8aa9af1416885e7badeae00b796 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|